Genzyme Plays Up Emerging Blood Cancer Business In R&D Review
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Genzyme has set its sights on emerging as a hematologic cancers specialist – a strategy made possible by a deal made in March, when it gained full rights to Campath from partner Bayer and brought in two additional blood cancer therapies.
You may also be interested in...
Mipomersen Brings Better-Than-Expected Phase III Results, But Some Questions Linger
Genzyme/Isis expect to file NDA for the cholesterol-lowering antisense drug in mid-2010.
Mipomersen Brings Better-Than-Expected Phase III Results, But Some Questions Linger
Genzyme/Isis expect to file NDA for the cholesterol-lowering antisense drug in mid-2010.
PTC Fully Enrolls Duchenne MD Trial; Expects Top-Line Data In Early 2010
With FDA approval of the six-minute walk test as primary endpoint, private specialty firm hopes to bring first Duchenne muscular dystrophy drug to market within two years.